Cel Sci Corporation (CVM)

[Fosco1]

I have been listening to the webcast, sorry hadn't had time before
I do find the tone convincing

1) He mentioned cancer stage III AND IV. That's an important point in our models as I have used basically stage III OAS curves, because IV includes metastatic which is not in the inclusion criteria.
He keeps on speaking on 55% survival at year 3. He reiterated that by the time the trial has been lasting the drug must be effective.
If he is right about the SOC survival, there is absolutely no doubt that the drug is very effective.

2) Reiterated that he didn't have access to the data but that IDMC and FDA had. And therefore allowed trial to continue in August 2018 having seen it.

3) Did not mention a date, but said 2019 will be an interesting year.

So my conclusion for it remains the same. The question is whether it is effective or very effective. If SOC is really nearly as bad as he mentions, no doubt it is very effective and endpoint should be reached before mid of year. Then he will need a bit of time for analysis and cleaning all the data, but then expect a result by Q3 or Q4 and a very very interesting year 2019 !